Evans’ syndrome following vaccination with ChAdOx1 nCoV-19 in a patient with new-onset localized scleroderma
https://doi.org/10.4081/dr.2022.9470
Accepted: 20 January 2022
HTML: 55
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Growing evidence suggests that COVID-19 vaccines can induce hematological conditions. Here, we report a case of Evans’ syndrome, a combination of immune thrombocytopenic purpura and autoimmune hemolytic anemia following administration of the ChAdOx1 nCoV-19 vaccine. The present case further supports the notion that COVID-19 vaccines can trigger in rare cases severe persistent autoimmune-mediated hematological conditions which may predominantly occur in patients with underlying autoimmune conditions.
Gambichler T, Boms S, Susok L, Dickel H, Finis C, Abu Rached N, Barras M, Stücker M, Kasakovski D. Cutaneous findings following COVID-19 vaccination: review of world literature and own experience. J Eur Acad Dermatol Venereol. 2021 Oct 17. doi: 10.1111/jdv.17744. DOI: https://doi.org/10.1111/jdv.17744
Akinosoglou K, Tzivaki I, Marangos M. Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon. Clin Immunol. 2021 May;226:108721. DOI: https://doi.org/10.1016/j.clim.2021.108721
McGonagle D, De Marco G, Bridgewood C. Mechanisms of Immunothrombosis in Vaccine-Induced Thrombotic Thrombocytopenia (VITT) Compared to Natural SARS-CoV-2 Infection. J Autoimmun. 2021 May 19;121:102662. DOI: https://doi.org/10.1016/j.jaut.2021.102662
Welsh KJ, Baumblatt J, Chege W, Goud R, Nair N. Thrombocytopenia including immune thrombocytopenia after receipt of mRNA COVID-19 vaccines reported to the Vaccine Adverse Event Reporting System (VAERS) [published online ahead of print, 2021 Apr 30]. Vaccine. 2021;39(25):3329-3332. DOI: https://doi.org/10.1016/j.vaccine.2021.04.054
Krajewski PK, Szepietowski JC. Immune thrombocytopenic purpura associated with COVID-19 Pfizer-BioNTech BNT16B2b2 mRNA vaccine. J Eur Acad Dermatol Venereol. 2021 Jun 2. doi: 10.1111/jdv.17444. Epub ahead of print. PMID: 34077572. DOI: https://doi.org/10.1111/jdv.17444
Hidaka D, Ogasawara R, Sugimura S, Fujii F, Kojima K, Nagai J, Ebata K, Okada K, Kobayashi N, Ogasawara M, Imamura M, Ota S. New-onset Evans syndrome associated with systemic lupus erythematosus after BNT162b2 mRNA COVID-19 vaccination. Int J Hematol. 2021 Oct 23:1–4. DOI: https://doi.org/10.1007/s12185-021-03243-2
Fattizzo B, Michel M, Giannotta JA, Hansen DL, Arguello Marina M, Sutto E, Bianchetti N, Patriarca A, Cantoni S, Mingot-Castellano ME, McDonald V, Capecchi M, Zaninoni A, Consonni D, Vos JMI, Vianelli N, Chen F, Glenthøj A, Frederiksen H, Gonzalez-Lopez TJ, Barcellini W. Evans syndrome in adults: an observational multicentre study. Blood Adv. 2021 Sep 30:bloodadvances.2021005610. doi: 10.1182/bloodadvan DOI: https://doi.org/10.1182/bloodadvances.2021005610
Malayala SV, Papudesi BN, Sharma R, Vusqa UT, Raza A. A Case of Idiopathic Thrombocytopenic Purpura After Booster Dose of BNT162b2 (Pfizer-Biontech) COVID-19 Vaccine. Cureus. 2021 Oct 23;13(10):e18985. DOI: https://doi.org/10.7759/cureus.18985
Okada Y, Sakai R, Sato-Fitoussi M, Nodera M, Yoshinaga S, Shibata A, Kurasawa T, Kondo T, Amano K. Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech. Front Med (Lausanne). 2021 Sep 30;8:751598. DOI: https://doi.org/10.3389/fmed.2021.751598
Radwi M, Farsi S. A case report of acquired hemophilia following COVID-19 vaccine. J Thromb Haemost. 2021 Jun;19(6):1515-1518. DOI: https://doi.org/10.1111/jth.15291
Copyright (c) 2022 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Citations
